Get 30% OFF every Mixing & Mastering Order : Discount Code MM30
Early preclinical studies have demonstrated the efficacy of Sone-214 in inhibiting tumor growth and reducing metastasis in a range of orthotopic and xenograft cancer models. For example, in NSCLC (non-small cell lung cancer) models, Sone-214 has been shown to reduce tumor burden by >50% compared to control animals, while also demonstrating potent anti-metastatic activity. Similarly, studies in breast cancer models have demonstrated that Sone-214 suppresses the growth of tumors and reduces the number of lung metastases by >70% compared to control animals.
Freedom‑to‑operate analysis (2023) indicates that SONE‑214 does infringe on the earlier DMXAA (5,6‑dimethylxanthenone‑4‑acetic acid) patents, nor on the cyclic dinucleotide space held by Merck (cGAMP) and ADU (ADU‑S100).
: Try searching for "sone-214" on the internet. This might lead you to product pages, technical specifications, user manuals, or forums where people discuss the item. sone-214
Sone-214 represents an exciting new development in cancer treatment, with its novel mechanism of action targeting the c-MET signaling pathway offering a promising approach to the treatment of various types of cancer. As clinical trials continue to evaluate the efficacy and safety of Sone-214, this small molecule inhibitor may emerge as a valuable addition to the oncology armamentarium, providing new hope for patients seeking effective and targeted cancer therapies.
The c-MET signaling pathway is a key regulator of cellular growth, survival, and motility in response to its ligand, hepatocyte growth factor (HGF). Aberrant activation of c-MET has been implicated in the development and progression of numerous cancers, leading to tumor aggression, chemotherapy resistance, and poor patient outcomes. The c-MET pathway has also been linked to the epithelial-to-mesenchymal transition (EMT) process, which enables cancer cells to acquire migratory and invasive properties, further complicating cancer treatment. Early preclinical studies have demonstrated the efficacy of
| Year
The central theme of SONE-214 is intense, messy, and drooling deep kissing ( zubburi ). The plot (insofar as JAV has one) revolves around a scenario where the actress and the male actor engage in extremely close, passionate kissing with a lot of saliva exchange, often leading to intercourse. The marketing emphasizes a "sticky, melting" love affair rather than a standard performance. Sone-214 represents an exciting new development in cancer
| Phase | Status | Key Milestones | |-------|--------|----------------| | | Completed 2022 (GLP tox, CMC) | IND submission to FDA (March 2023) | | Phase I (first‑in‑human, healthy volunteers) | Completed (Oct 2023) | • Single‑ascending dose (SAD) up to 150 mg – tolerable. • PK: Cmax at 2 h; half‑life ≈ 7 h; linear exposure 10‑150 mg. • PD: IFN‑β ↑ 3‑5‑fold at 50 mg; IL‑6 unchanged. • No serious adverse events (SAEs). | | Phase I/IIa (oncology – solid tumors) | Ongoing (as of Apr 2024) | • Open‑label, dose‑escalation (25‑100 mg PO daily) in patients with advanced melanoma, NSCLC, and pancreatic cancer. • Primary endpoint: safety/tolerability; secondary: ORR, PFS, immune‑gene signatures. | | Phase IIb (combination with anti‑PD‑1) | Planned for H2 2025 | • Multi‑center, randomized (SO‑214 + pembrolizumab vs. pembrolizumab alone) in refractory melanoma and head‑and‑neck SCC. | | Regulatory | IND active; fast‑track designation granted (FDA, Dec 2023) for “immunogenic tumor conversion”. | |
